Abbreviation	Full Name	Abbreviation	Full Name
PD-L1	Programmed death-ligand 1	EGFR	Epidermal growth factor receptor
PD1	Programmed cell death protein	DDR	DNA damage repair
ICIs	Immune checkpoint inhibitors	ESCC patients	Esophageal squamous cell carcinoma
TME	Tumor microenvironment	CHEK2	Checkpoint kinase 2
ECM	Extracellular matrix	ATM	Ataxia–telangiectasia mutation
TAMs	Tumor-associated macrophages	KRAS	Kirsten rat sarcoma virus
CAFs	Cancer-associated fibroblasts	TP53	Tumor Protein P53
TMB	Tumor mutational burden	SMARCA4	Transcription activator BRG1
Tregs	Regulatory T cells	BC	Breast cancer
MAPK	Ras/mitogen-activated protein kinase	FS	Frameshift mutations
PI3K	Phosphoinositide 3-kinase	TKIs	Tyrosine kinase inhibitors
mTOR	Mammalian target of rapamycin	HLA-I LOH	Human leukocyte antigen-I loss of heterozygosity
DC	Dendritic cells	PTEN	Phosphatase and tensin homolog
TCs	Ttumor cells	READ	Rectal adenocarcinoma
dMMR	Mismatch repair-deficient	METTL3	Methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit
MDSCs	mMyeloid-derived suppressor cells	EVs	Extracellular vesicles
MASH-HCC	Steatohepatitis -related hepatocellular carcinoma	CRISPR–Cas9	Clustered regularly interspaced short palindromic repeats-associated protein 9
SQLE	Squalene epoxidase	TRIM28-SETDB1	Tripartite Motif Containing 28-SET Domain Bifurcated Histone Lysine Methyltransferase 1
mCRC	Metastatic Colorectal Cancer	CD3E	CD3 Epsilon Subunit
HCC	Hepatocellular cancer	PDCD1	Programmed cell death protein 1
PaC	Pancreatic cancer	SV	Synthetic viability
ICB	Immune checkpoint blockade	iCCA	Intrahepatic cholangiocarcinoma
NK	Natural killer	IL1RN	Interleukin-1 receptor antagonist
CPS	Combined positive score	TMEM92	Transmembrane protein 92
LUAD	Lung adenocarciomaadenocarcinoma	rRCC	Renal cell carcinoma
LATPS	Tumor microenvironment prognostic signature	ASPSCR1-TFE3	Alveolar Soft Part Sarcoma Chromosome Region, Candidate 1–Transcription factor E3
IRGPI	Immune -related gene prognostic index	CTLA4	Cytotoxic T-lymphocyte associated protein 4
TIME	Tumor immunological microenvironment	FDA	Food and drugs administration
NMRGS	NAD+ metabolism-related gene signature	EMA	European medicines agency
NSCLC	Non-small -cell lung cancer	AGAs	Actionable oncogenic alterations
HNSCC	Head and neck squamous cell carcinoma	VEGF	Vascular endothelial growth factor
PDAC	Pancreatic ductal adenocarcinoma	R/M	Recurrent or metastatic
IML	Immune -mesenchymal -like	BRAF	B-Raf proto-oncogene, serine/threonine kinase
OS	Overall Survival	HER2	Receptor tyrosine-protein kinase erbB-2
DFS	Disease-free survival	PFS	Progression-free survival
NGS	Next-generation sequencing	TNBC	Triple-Negative Breast Cancer
TCGA	The Cancer Genome Atlas	SCLC	Small-cell lung cancer
IFΝγ	Interferon gamma	ICI	Immune cell infiltration
CAMs	Cell adhesion molecules	PBMCs	Blood mononuclear cells